---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-188881"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:20:08.045107+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tectonic Therapeutic receives FDA IND clearance for lead program TX45 in PH-HFpEF

## Summary
- FDA cleared IND for TX45 (Fc-relaxin fusion) for Group 2 PH due to HFpEF, a condition with no approved therapy affecting >600K US patients.
- Phase 1a healthy volunteer topline results due September 2024; Phase 1b patient hemodynamic topline results expected mid-2025.
- Phase 2 trial to start Q3 2024: 24-week SC dosing, up to 180 subjects; primary endpoint PVR change. Topline results anticipated in 2026.
- TX45 engineered for optimized pharmacology targeting vasodilation, diastolic dysfunction, and remodeling to improve exercise capacity.

## SEC filing metadata
- accession: 0001193125-24-188881
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312524188881/0001193125-24-188881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312524188881/d783068d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-188881
- JSON: https://secwatch.observer/filing/0001193125-24-188881.json
- Plain text: https://secwatch.observer/filing/0001193125-24-188881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.